BEGIN:VCALENDAR
VERSION:2.0
PRODID:https://murmitoyen.com/events/vanille/udem/
X-WR-TIMEZONE:America/Montreal
BEGIN:VEVENT
UID:69d3b74994421
DTSTAMP:20260406T093817
DTSTART:20110415T113000
SEQUENCE:0
TRANSP:OPAQUE
DTEND:20110415T123000
URL:https://murmitoyen.com/events/vanille/udem/detail/38234
LOCATION:Université de Montréal - Pavillon Claire-McNicoll\, 2900\, chemi
 n de la Tour\, Montréal\, QC\, Canada\, H3T 1J6
SUMMARY:Translation control of innate immunity and implication for viral on
 colysis
DESCRIPTION:Conférence du Dr Tommy Alain\, stagiaire post-doctoral\, du Mc
 Gill Cancer Center\, Cette conférence sera prononcée en anglais.Résum
 é The innate immune response constitutes the first line of defense agains
 t viral infection and type-I interferons (IFNs) are critical for this proc
 ess. A key regulation of innate immunity occurs at the level of translatio
 n\, and we have demonstrated that the kinase mTOR (mammalian target of rap
 amycin) and its downstream targets\, 4E-BPs and S6Ks\, are directly implic
 ated in this control. Oncolytic viruses constitute one of the most promisi
 ng novel anti-cancer therapies\, however virus-induced type-I IFN greatly 
 limits the clinical application of oncolytic viruses against malignant gli
 omas (MGs).We proposed that reducing type-I IFN production through the inh
 ibition of mTOR and its downstream targets would augment viral oncolysis o
 f MGs. We found the highly specific inhibitor of mTOR\, rapamycin\, in com
 bination with an IFN-sensitive VSV-mutant strain (VSVΔM51)\, dramatically
  increased the survival of immunocompetent rats bearing MGs. Importantly\,
  VSVΔM51 selectively killed tumor\, but not normal cells\, in MG-bearing 
 rats treated with rapamycin. These results demonstrate that reducing type 
 I IFNs through the inhibition of mTORC1 is an effective strategy to augmen
 t the therapeutic activity of VSVΔM51. The recent discovery of novel acti
 ve-site inhibitors of mTOR with inhibitory effects more potent than those 
 of rapamycin are presently studied in the lab\, and we anticipate that the
 ir combination with oncolytic viruses will have an increased therapeutic b
 enefit against MGs.Conférence présentée par le Département de microbio
 logie et immunologie de l'Université de Montréal. Crédit photo : site W
 eb du Département de microbiologie et immunologie 
END:VEVENT
BEGIN:VTIMEZONE
TZID:America/Montreal
X-LIC-LOCATION:America/Montreal
END:VTIMEZONE
END:VCALENDAR